{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:05:58Z","timestamp":1790370358798,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,24]],"date-time":"2020-12-24T00:00:00Z","timestamp":1608768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2020.100296","type":"journal-article","created":{"date-parts":[[2020,12,25]],"date-time":"2020-12-25T00:01:01Z","timestamp":1608854461000},"page":"100296","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":70,"special_numbering":"C","title":["Role of immunotherapy in bladder cancer"],"prefix":"10.1016","volume":"26","author":[{"given":"Logan P.","family":"Rhea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Mendez-Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanny B.","family":"Aragon-Ching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0001","first-page":"7","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0002","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World J Urol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0003","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: prostate and Bladder Tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.eururo.2016.06.040","article-title":"Trends in Bladder Cancer Incidence and Mortality: success or Disappointment?","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.eururo.2017.04.018","article-title":"Bladder Cancer in the Elderly","volume":"73","author":"Babjuk","year":"2018","journal-title":"Eur Urol"},{"issue":"17","key":"10.1016\/j.ctarc.2020.100296_bib0006","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1200\/JCO.2000.18.17.3068","article-title":"Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study","volume":"18","author":"von der Maase","year":"2000","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctarc.2020.100296_bib0007","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","article-title":"Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer","volume":"23","author":"von der Maase","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctarc.2020.100296_bib0008","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","article-title":"The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee","volume":"22","author":"Epstein","year":"1998","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0009","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: update","volume":"71","author":"Babjuk","year":"2016","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100296_bib0010","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/bju.14915","article-title":"Update on the guideline of guidelines: non-muscle-invasive bladder cancer","volume":"125","author":"Taylor","year":"2020","journal-title":"BJU Int"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100296_bib0011","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.eururo.2017.04.015","volume":"72","author":"Soukup","year":"2017","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0012","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1200\/JCO.2001.19.3.666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctarc.2020.100296_bib0013","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1016\/j.juro.2006.08.004","article-title":"Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium","volume":"176","author":"Shariat","year":"2006","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100296_bib0014","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.urolonc.2016.05.028","article-title":"Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations","volume":"34","author":"Kassouf","year":"2016","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0015","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.juro.2017.04.086","article-title":"Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA\/ASCO\/ASTRO\/SUO Guideline","volume":"198","author":"Chang","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.ctarc.2020.100296_bib0016","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1200\/EDBK_201227","article-title":"Multidisciplinary Management of Muscle-Invasive Bladder Cancer: current Challenges and Future Directions","volume":"38","author":"Aragon-Ching","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"9373","key":"10.1016\/j.ctarc.2020.100296_bib0017","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","article-title":"Advanced bladder cancer meta-analysis C. neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis","volume":"361","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0018","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.eururo.2012.05.048","article-title":"A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer","volume":"62","author":"Meeks","year":"2012","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.ctarc.2020.100296_bib0019","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.ctarc.2020.100296_bib0020","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2013.52.4785","article-title":"Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates","volume":"32","author":"Choueiri","year":"2014","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0021","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1200\/JCO.2020.38.6_suppl.437","volume":"38","author":"Culine","year":"2020","journal-title":"J Clinical Oncology"},{"issue":"17","key":"10.1016\/j.ctarc.2020.100296_bib0022","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \"unfit\" for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100296_bib0023","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.juro.2012.06.018","article-title":"Carboplatin based induction chemotherapy for nonorgan confined bladder cancer\u2013A reasonable alternative for cisplatin unfit patients?","volume":"188","author":"Mertens","year":"2012","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100296_bib0024","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0022-5347(17)39672-6","article-title":"Randomized phase II evaluation of carboplatin and CHIP in advanced transitional cell carcinoma of the urothelium. The Eastern Cooperative Oncology Group","volume":"144","author":"Trump","year":"1990","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100296_bib0025","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.juro.2016.06.049","article-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Guideline","volume":"196","author":"Chang","year":"2016","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0026","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.ju.0000073852.24341.4a","article-title":"Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer","volume":"170","author":"Bohle","year":"2003","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0027","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrurol.2014.15","article-title":"The mechanism of action of BCG therapy for bladder cancer\u2013a current perspective","volume":"11","author":"Redelman-Sidi","year":"2014","journal-title":"Nat Rev Urol"},{"issue":"7463","key":"10.1016\/j.ctarc.2020.100296_bib0028","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ctarc.2020.100296_bib0029","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1634\/theoncologist.2017-0087","article-title":"FDA Approval Summary: atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy","volume":"22","author":"Ning","year":"2017","journal-title":"Oncologist"},{"issue":"10064","key":"10.1016\/j.ctarc.2020.100296_bib0030","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"7528","key":"10.1016\/j.ctarc.2020.100296_bib0031","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","article-title":"MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer","volume":"515","author":"Powles","year":"2014","journal-title":"Nature"},{"issue":"10031","key":"10.1016\/j.ctarc.2020.100296_bib0032","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"10122","key":"10.1016\/j.ctarc.2020.100296_bib0033","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial","volume":"391","author":"Powles","year":"2018","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctarc.2020.100296_bib0034","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.ctarc.2020.100296_bib0035","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1200\/JCO.2017.76.9562","article-title":"Health-Related Quality-of-Life Analysis From KEYNOTE-045: a Phase III Study of Pembrolizumab Versus Chemotherapy for Previously Treated Advanced Urothelial Cancer","volume":"36","author":"Vaughn","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100296_bib0036","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S1470-2045(17)30239-5","article-title":"Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial","volume":"18","author":"Heery","year":"2017","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctarc.2020.100296_bib0037","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1200\/JCO.2016.71.6795","article-title":"Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: results From a Multicenter, Phase Ib Study","volume":"35","author":"Apolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0038","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(17)30900-2","article-title":"Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial","volume":"19","author":"Patel","year":"2018","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.ctarc.2020.100296_bib0039","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.ctarc.2020.100296_bib0040","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/S1470-2045(16)30496-X","article-title":"Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1\/2 trial","volume":"17","author":"Sharma","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctarc.2020.100296_bib0041","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1200\/JCO.19.00538","article-title":"Nivolumab Alone and With Ipilimumab in Previously Treated Metastatic Urothelial Carcinoma: checkMate 032 Nivolumab 1 mg\/kg Plus Ipilimumab 3 mg\/kg Expansion Cohort Results","volume":"37","author":"Sharma","year":"2019","journal-title":"J Clin Oncol"},{"issue":"26","key":"10.1016\/j.ctarc.2020.100296_bib0042","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctarc.2020.100296_bib0043","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.2411","article-title":"Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: updated Results From a Phase 1\/2 Open-label Study","volume":"3","author":"Powles","year":"2017","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctarc.2020.100296_bib0044","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/EDBK_237451","article-title":"Formidable scenarios in urothelial and variant cancers of the urinary tract","volume":"39","author":"Aragon-Ching","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100296_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/his.12996","article-title":"PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation","volume":"69","author":"Cree","year":"2016","journal-title":"Histopathology"},{"issue":"10236","key":"10.1016\/j.ctarc.2020.100296_bib0046","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ctarc.2020.100296_bib0047","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.ctarc.2020.100296_bib0048","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1200\/JCO.19.01213","article-title":"Long-Term Outcomes in KEYNOTE-052: phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer","volume":"38","author":"Vuky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0049","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1200\/JCO.2020.38.6_suppl.441","article-title":"Study EV-103: preliminary durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clinical Oncology"},{"key":"10.1016\/j.ctarc.2020.100296_bib0050","doi-asserted-by":"crossref","first-page":"S1155","DOI":"10.1016\/j.annonc.2020.08.2252","article-title":"LBA23 Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361","volume":"31","author":"Alva","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctarc.2020.100296_bib0051","doi-asserted-by":"crossref","first-page":"S550","DOI":"10.1016\/j.annonc.2020.08.769","article-title":"697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)","volume":"31","author":"Powles","year":"2020","journal-title":"Annals of Oncology"},{"issue":"5","key":"10.1016\/j.ctarc.2020.100296_bib0052","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cncr.28477","article-title":"Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma","volume":"120","author":"Grivas","year":"2014","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2020.100296_bib0053","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1200\/JCO.2015.66.3468","article-title":"Phase III, double-blind, randomized trial that compared maintenance lapatinib versus placebo after first-line chemotherapy in patients with human epidermal growth factor receptor 1\/2-Positive metastatic bladder cancer","volume":"35","author":"Powles","year":"2017","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.ctarc.2020.100296_bib0054","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1200\/JCO.19.03091","article-title":"Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients with metastatic urothelial cancer","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.ctarc.2020.100296_bib0055","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctarc.2020.100296_bib0056","doi-asserted-by":"crossref","first-page":"S552","DOI":"10.1016\/j.annonc.2020.08.771","article-title":"699O Avelumab first-line (1L) maintenance\u00a0+\u00a0best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers","volume":"31","author":"Powles","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.ctarc.2020.100296_bib0057","doi-asserted-by":"crossref","first-page":"S578","DOI":"10.1016\/j.annonc.2020.08.817","article-title":"745P Patient-reported outcomes (PROs) from JAVELIN Bladder 100: avelumab first-line (1L) maintenance\u00a0+\u00a0best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC)","volume":"31","author":"Powles","year":"2020","journal-title":"Annals of Oncology"},{"issue":"11","key":"10.1016\/j.ctarc.2020.100296_bib0058","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"34","key":"10.1016\/j.ctarc.2020.100296_bib0059","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): an Open-Label, Single-Arm, Phase II Study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100296_bib0060","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.2217\/fon-2019-0611","article-title":"ENERGIZE: a Phase III study of neoadjuvant chemotherapy alone or with nivolumab with\/without linrodostat mesylate for muscle-invasive bladder cancer","volume":"16","author":"Sonpavde","year":"2020","journal-title":"Future Oncol"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0061","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4592","volume":"37","author":"Powles","year":"2019","journal-title":"J Clinical Oncology"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0062","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS599","article-title":"Phase III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866","volume":"38","author":"Siefker-Radtke","year":"2020","journal-title":"J Clinical Oncology"},{"issue":"6_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0063","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.TPS593","article-title":"Phase III study of perioperative pembrolizumab (pembro) plus cystectomy versus cystectomy alone in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-905","volume":"38","author":"Galsky","year":"2020","journal-title":"J Clinical Oncology"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0064","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.5000","article-title":"IMvigor010: primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC)","volume":"38","author":"Hussain","year":"2020","journal-title":"J Clinical Oncology"},{"issue":"7_suppl","key":"10.1016\/j.ctarc.2020.100296_bib0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1200\/JCO.2019.37.7_suppl.350","article-title":"Keynote 057: phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG)","volume":"37","author":"Balar","year":"2019","journal-title":"J Clinical Oncology"},{"issue":"10","key":"10.1016\/j.ctarc.2020.100296_bib0066","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2217\/fon-2019-0817","article-title":"KEYNOTE-676: phase III study of BCG and pembrolizumab for persistent\/recurrent high-risk NMIBC","volume":"16","author":"Kamat","year":"2020","journal-title":"Future Oncol"},{"issue":"2","key":"10.1016\/j.ctarc.2020.100296_bib0067","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/14737140.2018.1421461","article-title":"Pembrolizumab for the treatment of bladder cancer","volume":"18","author":"Sundahl","year":"2018","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ctarc.2020.100296_bib0068","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1634\/theoncologist.2018-0084","article-title":"FDA Approval Summary: atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy","volume":"24","author":"Suzman","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.ctarc.2020.100296_bib0069","first-page":"1","article-title":"Maintenance avelumab for metastatic urothelial cancer: a new standard of care","author":"Erck","year":"2020","journal-title":"Cancer Biol Ther"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294220301313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:22:41Z","timestamp":1762842161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294220301313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":69,"alternative-id":["S2468294220301313"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of immunotherapy in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2020.100296","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100296"}}